Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.10.010
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Clinical Medicine Insights: Oncology
Oncology
2011English

Clinical and Economic Outcomes of Treatment Sequences for Intermediate- To Poor-Risk Advanced Renal Cell Carcinoma

Immunotherapy
OncologyAllergyImmunology
2020English

Real‐world Progression, Treatment, and Survival Outcomes During Rapid Adoption of Immunotherapy for Advanced Non–small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2019English

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2019English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy